Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

56 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-02-03

Study Completion Date

2019-08-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To Calculate the amount radiation the lung receives in patients receiving Yttrium-90 for Liver Cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Optimizing Y90 Therapy for Radiation Lobectomy

NCT04390724

HCC Resection Transplant +2 more

RECRUITING

Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

NCT03686709

Hepatocellular Carcinoma Radiation Exposure

RECRUITING NA

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

NCT04518748

Liver Malignancy

RECRUITING PHASE1

Y-90 Versus SBRT for Inoperable HCC

NCT05157451

Hepatocellular Carcinoma Stage I Hepatocellular Carcinoma AJCC v8 Stage IA Hepatocellular Carcinoma AJCC v8 +6 more

WITHDRAWN PHASE2

Streamlined Resin Y90 Radiation Segmentectomy for Small HCC

NCT06618300

Hepatocellular Carcinoma (HCC)

ENROLLING_BY_INVITATION

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To calculate the delivered lung dose using quantitative volumetric analysis in a cohort of patients with unresectable hepatocellular carcinoma who undergo selective internal radiation therapy (SIRT) with Yttrium-90 glass microspheres (TheraSphere®)-and compare this analysis to the lung dose estimated by established criteria. In addition, this study, will summarize the pre and post-treatment clinical data to describe the URMC Y-90 experience.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults ≥ 18 years with no upper limit.-Receiving Y-90 Therasphere liver directed therapy
* Pathology proven diagnosis of hepatocellular carcinoma, metastatic colon cancer or other metastatic diseases to be treated with SIRT (Y-90)
* surgical resection not feasible at time of initiation of pre-treatment workup

-\> 6 months projected life span
* ECOG 0-2

Exclusion Criteria

* previous radioembolization of one or more liver lobes or segments without available treatment planning and procedural documentation ie. at another facility prior to URMC Y-90 radioembolization.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No